Gilead Oncology Triple Negative Overview | GileadPro

Triple-negative breast cancer is a less common type of breast cancer.² It is defined by its lack of human epidermal growth factor receptor 2 (HER2), oestrogen and progesterone receptors.¹ Compared with other breast cancers, its tumours tend to be:^4–8

• faster growing
• less differentiated and of a higher histologic grade
• larger at diagnosis

Triple-negative breast cancer can be aggressive, is associated with a high rate of recurrence, and has a poor survival rate compared with other breast cancers.^1,3,4

Clinical needs in triple-negative breast cancer

Dr Fiona MacLean, Senior Medical Affairs Operations Manager at Kite, a Gilead Company, discusses the main characteristics of triple-negative breast cancer in this video, including:

• Definition and epidemiology
• Incidence as a proportion of invasive breast cancers
• Risk factors and median age at diagnosis
• Prognosis compared to other subtypes
• Metastatic triple-negative breast cancer (mTNBC)

(05:30 minutes)

References:

1. Fangyuan, S, et al. Oncotarget. 2017;8(42):73329-73344.
2. Cancer Research UK. Breast cancer statistics. Available at: https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/breast-cancer. Accessed: January 2024.
3. Seah DS, et al. J Natl Compr Canc Netw. 2014;12(1):71-80.
4. American Cancer Society. Triple-negative Breast Cancer. Available at: https://www.cancer.org/cancer/breast-cancer/understanding-a-breast-cancer-diagnosis/types-of-breast-cancer/triple-negative.html. Accessed: January 2024.
5. Foulkes WD, et al. N Engl J Med. 2010;363(20):1938-1948.
6. Lebert JM, et al. Curr Oncol. 2018;25(Suppl 1):S142-s50.
7. Sharma P. Oncologist. 2016;21(9):1050-1062.
8. Lee A, Djamgoz MBA. Cancer Treat Rev. 2018;62:110-22.